Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
eSense-Lab. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
eSense-Lab's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as eSense-Lab has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare eSense-Lab's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare eSense-Lab's earnings growth to the Australia market average as no estimate data is available.
Unable to compare eSense-Lab's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if eSense-Lab is high growth as no earnings estimate data is available.
Unable to determine if eSense-Lab is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
eSense-Lab's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Itzik Mizrahi has been Chief Executive Officer of eSense-Lab Limited since March 9, 2020. Mr. Mizrahi leans on this experience to has renewed vigour to eSense’s business strategy at a critical time for eSense as it prepares for a new wave of technological development and revenue growth. He believes that eSense’s superior platform, technology and unique IP profile places eSense in an advantageous position as it expands and commences commercialisation on the global scale. Mr. Itzik Mizrahi served as Head of Clinical at Pfizer Pharmaceuticals Israel, and General Manager at Actelion Pharmaceuticals Israel and he had full accountability for clinical departments, operational efficiency and regulatory compliance. Mr. Mizrahi has a wealth of experience in global big pharma, with many years tenure in management positions.
Insufficient data for Itzik to compare compensation growth.
Insufficient data for Itzik to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Mira Carmeli Weissberg
Chief Scientific Officer
Chief Executive Officer
Chief Financial Officer
Chief Technology Officer
Head of the Bio-Botanic Unit
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the eSense-Lab board of directors is less than 3 years, this suggests a new board.
Board of Directors
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
What Kind Of Investor Owns Most Of eSense-Lab Limited (ASX:ESE)?
A look at the shareholders of eSense-Lab Limited (ASX:ESE) can tell us which group is most powerful. … eSense-Lab is not a large company by global standards. … Let's take a closer look to see what the different types of shareholder can tell us about ESE
What Type Of Shareholder Owns eSense-Lab Limited's (ASX:ESE)?
Generally speaking, as a company grows, institutions will increase their ownership. … Conversely, insiders often decrease their ownership over time. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'.
Was eSense-Lab Limited's (ASX:ESE) Earnings Growth Better Than The Industry's?
When eSense-Lab Limited (ASX:ESE) released its most recent earnings update (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … See our latest analysis for eSense-Lab Were ESE's earnings stronger than its past performances and the industry? … For eSense-Lab, its most recent earnings (trailing twelve month) is -US$2.11M, which, against last year’s level, has become less negative.
What You Must Know About eSense-Lab Limited's (ASX:ESE) Major Investors
Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … General Public Ownership The general public holds 5.54% stake in ESE, thus, representing an important class of owners. … This size of ownership, while considerably large for a public company, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Breakeven On The Horizon For eSense-Lab Ltd (ASX:ESE)
ASX:ESE Past Future Earnings Mar 30th 18 Given this is a high-level overview, I won’t go into detail the detail of ESE’s upcoming projects, though, keep in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. … Next Steps: This article is not intended to be a comprehensive analysis on ESE, so if you are interested in understanding the company at a deeper level, take a look at ESE’s company page on Simply Wall St. … Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
Should You Invest In The Healthcare Stock eSense-Lab Ltd (ASX:ESE)?
Unsuprisingly, this is below the growth rate of the Australian stock market as a whole. … In the past year, the industry delivered growth in the teens, beating the Australian market growth of 7.19%. … If eSense-Lab has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.
Cash is crucial to run a business, and if a company burns through its reserves fast, it will need to come back to market for additional capital raising. … Cash burn is when a loss-making company spends its equity to fund its expenses before making money from its day-to-day business. … Companies with high cash burn rates can eventually turn into ashes, which makes it the biggest risk an investor in loss-making companies face.
eSense-Lab Limited, a life sciences research and development company, specializes in the commercialization of phytochemical profiling of plants. The company focuses on the development and manufacturing of terpene profiles of the cannabis plant for use in various applications, such as concentrates, medicine, topical treatments, e-liquids, beverages, personalized medicine, cosmetics, and food additives. eSense-Lab Limited was incorporated in 2016 and is based in Nes Tziona, Israel.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.